Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Amit Sanyal, MD: A Clinician’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Dec

Today In Oncology

Regular Screening Mammograms May Significantly Reduce Breast Cancer Mortality, Swedish Study Shows

Toxicities Potentially Linked to Combination Immunotherapy for Mesothelioma

Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC

Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors

Inotuzumab Ozogamicin–Based Induction in Older Patients With Philadelphia Chromosome–Negative B-Cell–Precursor ALL

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?